An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating ...

Preventing onset and development of heart failure with preserved ejection fraction Date: April 15, 2025 Source: Baylor College of Medicine Summary: An international team of researchers has ...

The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

Preventing Onset and Development of Heart Failure With Preserved Ejection Fraction Apr. 15, 2025 — An international team of researchers has discovered a natural mechanism that protects the heart ...

Tirzepatide has also been shown to improve health status and lower the risk of death in people with obesity and heart failure with preserved ejection fraction. You don’t have control over all the ...

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to ...